Spent a while on this: 2026 bulls

u/batdog44 · Reddit — r/stocks · January 26, 2026 at 16:49 · 💬 3 comments  | View on Reddit ↗
AI Summary

Original Reddit post

Author presents a hand-picked list of 2026 bullish stock ideas with fundamental and technical rationales, including margin expansion, buybacks, backlog, AI growth, and valuation catalysts.

ACN — LONG Author argues Accenture is making strong progress with AI, showing a 10% year-over-year increase in managed services and expected better operating margins in fiscal 2026. Technical indicators with solid volume and momentum could drive further gains.

Accenture is making strong progress with AI, showing a 10% year-over-year increase in managed services and better operating margins expected in fiscal 2026.

ADP — LONG Author claims ADP is a reliable performer with consistent earnings and dividends, setting up for about 31% total returns in 2026 due to steady growth and an attractive entry point from recent market dips. The mechanism is steady growth and an attractive entry point.

ADP is a reliable performer with consistent earnings and dividends, setting up for about 31% total returns in 2026 due to steady growth and an attractive entry point from recent market dips.

BIIB — LONG Author states Biogen’s pipeline is advancing, including EU approval for a high-dose version of Spinraza, which strengthens the positive outlook. Combined with stable earnings and a recent 9% stock rise, it points to recovery potential.

Biogen’s pipeline is advancing, including EU approval for a high-dose version of Spinraza, which strengthens the positive outlook. Combined with stable earnings and a recent 9% stock rise, it points to recovery potential.

CHDN — LONG Author argues Churchill Downs benefits from its strong brand and investments in luxury experiences like Derby suites, along with share buybacks that have reduced outstanding shares by 30% over the past decade. Analysts expect a higher valuation from new track developments.

Churchill Downs benefits from its strong brand and investments in luxury experiences like Derby suites, along with share buybacks that have reduced outstanding shares by 30% over the past decade. Analysts expect a higher valuation from new track developments.

CLX — LONG Author views Clorox as attractively valued at 16 times forward earnings given over 35% return on invested capital. The lower multiples offer value and consistent demand for household essentials should drive a recovery.

Clorox is trading at an attractive 16 times forward earnings, given its over 35% return on invested capital. The lower multiples offer value, and consistent demand for household essentials should drive a recovery.

CNC — LONG Author believes Centene appears undervalued at current multiples, with stable earnings and the possibility of trading at 14 times 2026 earnings per share. Government-related risks are stated, but improvements in margins could shift sentiment positively.

Centene appears undervalued at current multiples, with stable earnings and the possibility of trading at 14 times 2026 earnings per share. While there are government-related risks, improvements in margins could shift sentiment positively.

LIN — LONG Author highlights Linde has a backlog of $7 to $10 billion in long-term contracts, supporting over 10% earnings per share growth. Analysts remain positive about its consistent expansion and long-term compounding ability.

Linde has a backlog of $7 to $10 billion in long-term contracts, supporting over 10% earnings per share growth. Analysts remain positive about its consistent expansion and long-term compounding ability.

MCK — LONG Author argues McKesson seems undervalued by about 41% based on discounted cash flow analysis, with ongoing benefits from GLP-1 trends into 2026. Its strong performance over recent years indicates room for further progress.

McKesson seems undervalued by about 41% based on discounted cash flow analysis, with ongoing benefits from GLP-1 trends into 2026. Its strong performance over recent years indicates room for further progress.

NOW — LONG Author claims ServiceNow’s AI efforts could generate over $1 billion in annual recurring revenue by 2026, attracting hedge funds and positive analyst views. Despite a 28% decline, the setup suggests a possible rebound.

ServiceNow’s AI efforts could generate over $1 billion in annual recurring revenue by 2026, attracting hedge funds and positive analyst views. Despite a 28% decline, the setup suggests a possible rebound.

PAYX — LONG Author says Paychex looks undervalued with expected revenue growth ahead. A partnership with PayPal enhances sentiment, targeting potential upside to $133 based on its recurring business model.

Paychex looks undervalued with expected revenue growth ahead. A partnership with PayPal enhances sentiment, targeting potential upside to $133 based on its recurring business model.

STLA — LONG Author notes Stellantis has been upgraded to overweight, with leadership changes and $13 billion in U.S. investments aimed at sales recovery by 2026. The current dip presents value opportunities.

Stellantis has been upgraded to overweight, with leadership changes and $13 billion in U.S. investments aimed at sales recovery by 2026. The current dip presents value opportunities.

UNH — LONG Author believes UnitedHealth could return to all-time highs in 2026 through adjustments in care ratios. Undervaluation suggests upside to over $400 per share in positive scenarios.

UnitedHealth could return to all-time highs in 2026 through adjustments in care ratios, with undervaluation suggesting upside to over $400 per share in positive scenarios.

Comments 3
Full Post Text
Ideas
u/batdog44 Reddit r/stocks
AI progress, margin expansion, fiscal 2026 upside.
Author argues Accenture is making strong progress with AI, showing a 10% year-over-year increase in managed services and expected better operating margins in fiscal 2026. Technical indicators with solid volume and momentum could drive further gains.
u/batdog44 Reddit r/stocks
Steady earnings and dividends with 31% 2026 return setup.
Author claims ADP is a reliable performer with consistent earnings and dividends, setting up for about 31% total returns in 2026 due to steady growth and an attractive entry point from recent market dips. The mechanism is steady growth and an attractive entry point.
u/batdog44 Reddit r/stocks
EU Spinraza approval plus stable earnings recovery.
Author states Biogen’s pipeline is advancing, including EU approval for a high-dose version of Spinraza, which strengthens the positive outlook. Combined with stable earnings and a recent 9% stock rise, it points to recovery potential.
u/batdog44 Reddit r/stocks
Buybacks and new tracks drive higher valuation.
Author argues Churchill Downs benefits from its strong brand and investments in luxury experiences like Derby suites, along with share buybacks that have reduced outstanding shares by 30% over the past decade. Analysts expect a higher valuation from new track developments.
u/batdog44 Reddit r/stocks
Cheap 16x forward earnings with 35% ROIC recovery.
Author views Clorox as attractively valued at 16 times forward earnings given over 35% return on invested capital. The lower multiples offer value and consistent demand for household essentials should drive a recovery.
u/batdog44 Reddit r/stocks
Undervalued at 14x 2026 EPS despite government risks.
Author believes Centene appears undervalued at current multiples, with stable earnings and the possibility of trading at 14 times 2026 earnings per share. Government-related risks are stated, but improvements in margins could shift sentiment positively.
u/batdog44 Reddit r/stocks
Backlog supports over 10% EPS growth compounding.
Author highlights Linde has a backlog of $7 to $10 billion in long-term contracts, supporting over 10% earnings per share growth. Analysts remain positive about its consistent expansion and long-term compounding ability.
u/batdog44 Reddit r/stocks
41% DCF undervaluation and GLP-1 tailwind into 2026.
Author argues McKesson seems undervalued by about 41% based on discounted cash flow analysis, with ongoing benefits from GLP-1 trends into 2026. Its strong performance over recent years indicates room for further progress.
u/batdog44 Reddit r/stocks
AI ARR growth with possible rebound after 28% decline.
Author claims ServiceNow’s AI efforts could generate over $1 billion in annual recurring revenue by 2026, attracting hedge funds and positive analyst views. Despite a 28% decline, the setup suggests a possible rebound.
u/batdog44 Reddit r/stocks
Undervalued Paychex with PayPal partnership and $133 upside.
Author says Paychex looks undervalued with expected revenue growth ahead. A partnership with PayPal enhances sentiment, targeting potential upside to $133 based on its recurring business model.
u/batdog44 Reddit r/stocks
Overweight upgrade and $13B U.S. investment recovery.
Author notes Stellantis has been upgraded to overweight, with leadership changes and $13 billion in U.S. investments aimed at sales recovery by 2026. The current dip presents value opportunities.
u/batdog44 Reddit r/stocks
Care ratio fixes could return UNH to $400+.
Author believes UnitedHealth could return to all-time highs in 2026 through adjustments in care ratios. Undervaluation suggests upside to over $400 per share in positive scenarios.
More from Reddit — r/stocks

This Reddit post, published January 26, 2026, features u/batdog44 discussing ACN, ADP, BIIB, CHDN, CLX, CNC, LIN, MCK, NOW, PAYX, STLA, UNH. 12 trade ideas extracted by AI with direction and confidence scoring.

Speakers: u/batdog44  · Tickers: ACN, ADP, BIIB, CHDN, CLX, CNC, LIN, MCK, NOW, PAYX, STLA, UNH